Dyskinesia Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Teva Pharma, Neurocrine Biosciences, Inc, Sun Pharma, SteriMax Inc., Adamas Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dyskinesia pipeline constitutes 45+ key companies continuously working towards developing 45+ Dyskinesia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Dyskinesia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dyskinesia Market.

The Dyskinesia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Dyskinesia Pipeline Report: https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Dyskinesia treatment therapies with a considerable amount of success over the years.
• Dyskinesia companies working in the treatment market are PolyCore Therapeutics, Melior Pharmaceuticals, MapLight Therapeutics, Luye Pharma Group, Contera Pharma, Neurolixis, Celon Pharma, and others, are developing therapies for the Dyskinesia treatment
• Emerging Dyskinesia therapies in the different phases of clinical trials are- PCT-3012, Mesocarb, ML 007, LY 03015, JM-010, NLX 112, CPL 500036, and others are expected to have a significant impact on the Dyskinesia market in the coming years.
• In May 2022, At the American mental Association Annual Meeting in 2022, Neurocrine Biosciences presented updated INGREZZA (valbenazine) data on tardive dyskinesia improvement and stability of mental symptoms.
• In August 2021, Results of a post hoc analysis of a long-term, three-year open-label extension (OLE) study examining efficacy and safety endpoints for the use of AUSTEDO (Deutetrabenazine) tablets in younger (55 years old) and older (55 years old) patients with tardive dyskinesia (TD) were released by Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd. in the United States.
• In April 2021, A randomized, double-blind, placebo-controlled, two-part study was started by Bukwang Pharmaceutical with the goal of determining the effectiveness and safety/tolerability of fixed dose combinations of JM-010 and its individual components in patients with Parkinson's disease who also had dyskinesia.

Dyskinesia Overview
A movement disorder called dyskinesia frequently manifests as uncontrollably shaking, ticing, or trembling. People who have Parkinson's disease frequently develop the condition as a result of drugs that overstimulate their dopamine receptors, increasing this neurotransmitter in the brain.

Get a Free Sample PDF Report to know more about Dyskinesia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Dyskinesia Drugs Under Different Phases of Clinical Development Include:
• PCT-3012: PolyCore Therapeutics
• Mesocarb: Melior Pharmaceuticals
• ML 007: MapLight Therapeutics
• LY 03015: Luye Pharma Group
• JM-010 : Contera Pharma
• NLX 112: Neurolixis
• CPL 500036: Celon Pharma

Dyskinesia Route of Administration
Dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Dyskinesia Molecule Type
Dyskinesia Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Dyskinesia Pipeline Therapeutics Assessment
• Dyskinesia Assessment by Product Type
• Dyskinesia By Stage and Product Type
• Dyskinesia Assessment by Route of Administration
• Dyskinesia By Stage and Route of Administration
• Dyskinesia Assessment by Molecule Type
• Dyskinesia by Stage and Molecule Type

DelveInsight's Dyskinesia Report covers around 45+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Dyskinesia product details are provided in the report. Download the Dyskinesia pipeline report to learn more about the emerging Dyskinesia therapies at:
https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Dyskinesia Therapeutics Market include:
Key companies developing therapies for Dyskinesia are - Teva Pharmaceutical, Neurocrine Biosciences, Inc, Sun Pharmaceutical, SteriMax Inc., Adamas Pharmaceuticals, Inc, Sanis, AbbVie Inc, and others.

Dyskinesia Pipeline Analysis:
The Dyskinesia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Dyskinesia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dyskinesia Treatment.
• Dyskinesia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dyskinesia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dyskinesia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Dyskinesia drugs and therapies-
https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dyskinesia Pipeline Market Drivers
• Increase in prevalence of Dyskinesia, increase in the demand for disease specific novel treatment are some of the important factors that are fueling the Dyskinesia Market.

Dyskinesia Pipeline Market Barriers
• However, lack of understanding of the pharmacology of Dyskinesia, side-effects associated with drugs and other factors are creating obstacles in the Dyskinesia Market growth.

Scope of Dyskinesia Pipeline Drug Insight
• Coverage: Global
• Key Dyskinesia Companies: PolyCore Therapeutics, Melior Pharmaceuticals, MapLight Therapeutics, Luye Pharma Group, Contera Pharma, Neurolixis, Celon Pharma, and others
• Key Dyskinesia Therapies: PCT-3012, Mesocarb, ML 007, LY 03015, JM-010, NLX 112, CPL 500036, and others
• Dyskinesia Therapeutic Assessment: Dyskinesia current marketed and Dyskinesia emerging therapies
• Dyskinesia Market Dynamics: Dyskinesia market drivers and Dyskinesia market barriers

Request for Sample PDF Report for Dyskinesia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Dyskinesia Report Introduction
2. Dyskinesia Executive Summary
3. Dyskinesia Overview
4. Dyskinesia- Analytical Perspective In-depth Commercial Assessment
5. Dyskinesia Pipeline Therapeutics
6. Dyskinesia Late Stage Products (Phase II/III)
7. Dyskinesia Mid Stage Products (Phase II)
8. Dyskinesia Early Stage Products (Phase I)
9. Dyskinesia Preclinical Stage Products
10. Dyskinesia Therapeutics Assessment
11. Dyskinesia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Dyskinesia Key Companies
14. Dyskinesia Key Products
15. Dyskinesia Unmet Needs
16 . Dyskinesia Market Drivers and Barriers
17. Dyskinesia Future Perspectives and Conclusion
18. Dyskinesia Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others

B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.